Microdosing and mental health — what the research actually says

Microdosing — taking sub-perceptual amounts of psychedelic substances, typically psilocybin or LSD, on a regular schedule — has attracted significant popular interest in the last decade. The anecdotal reports are enthusiastic. The research is more complicated.

Here's what the evidence actually shows, without either dismissing the reports or overstating what's been established.

Key takeaways

• Microdosing refers to taking sub-perceptual doses of psychedelics, typically on a schedule like one day on, two days off

• Anecdotal reports are often positive, describing improved mood, focus, creativity, and reduced anxiety

• Controlled research has been harder to conduct due to regulatory constraints, but is growing

• Placebo effects appear to be significant in microdosing studies — expectation and belief produce measurable effects

• The evidence doesn't yet clearly establish that microdosing produces effects beyond placebo for most outcomes, but research is ongoing

What people report

People who microdose report a range of benefits: improved mood and emotional regulation, reduced anxiety and depression, increased creativity and cognitive flexibility, improved focus and productivity, greater sense of connection and meaning. These reports come from large observational studies as well as from the extensive online and community-based literature.

What the research shows

Controlled research on microdosing is difficult because psychedelics are detectable by users, which complicates true double-blinding. The studies that have been done have generally found:

• Positive effects on mood, focus, and wellbeing in uncontrolled studies

• Significant placebo effects — participants who believed they received active doses showed benefits even when they received placebo

• In better-controlled studies, the benefit over placebo has been less clear or inconsistent

• Some studies have found increased anxiety and discomfort in some participants

• No serious adverse events in typical microdosing protocols in research settings

What this means practically

The honest summary is: some people appear to benefit from microdosing, placebo effects are real and not trivial, and we don't yet have enough rigorous evidence to confidently say what the specific effects of the substance are beyond expectation. That doesn't mean it doesn't work for individuals — it means we need more research.

If you're considering microdosing for mental health reasons, discussing it with a therapist familiar with psychedelic approaches — and being honest about your expectations and monitoring actual effects — is more useful than going in with only anecdotal information.

Frequently asked questions

Is microdosing safe?

At the doses typically used, the direct safety profile appears reasonable — no toxicity has been identified at sub-perceptual doses in research. The main risks are psychological: some people experience increased anxiety, emotional sensitivity, or disrupted sleep. Legal risk remains relevant in Canada, where psilocybin remains a controlled substance outside of approved contexts.

What's the typical microdosing schedule?

The most commonly described protocol — associated with James Fadiman's early work — is one day on, two days off. This is meant to prevent tolerance and allow observation of effects. Other schedules (every other day, 4 days on / 3 off) are also used. None of these has been systematically compared in rigorous trials.

Should I tell my therapist if I'm microdosing?

Yes, if you trust them to hold the information non-judgmentally. Psychedelics — even at sub-perceptual doses — can affect emotional sensitivity and processing, which may be relevant to your therapy. A therapist familiar with psychedelic approaches won't pathologize the choice and can help you monitor effects meaningfully.